Paul Cayer

Paul Cayer is an accomplished finance executive with extensive experience in the healthcare sector. Currently serving as Chief Financial Officer at Engrail Therapeutics since July 2024, Cayer previously held the same position at Ashvattha Therapeutics from May 2023 to July 2024. Prior to that, Cayer was Chief Financial and Business Officer at Otonomy Inc. from October 2008 to March 2023, and held senior roles including SVP Corporate Development at Verus Pharmaceuticals and SVP Business Development and CFO at Targeted Molecules Corp. Cayer began a career in various healthcare consulting roles from 1999 to 2001 and served as VP Marketing and Business Development at Gensia, Inc. from 1993 to 1999. Cayer holds an MBA from Harvard Business School and a Bachelor's degree in Biomechanical Engineering from Harvard University.